Does TRICARE Cover Mounjaro?

TRICARE Formulary Placement for Mounjaro

TRICARE places Mounjaro (tirzepatide) on its non-preferred specialty formulary tier, which carries higher cost-sharing than preferred brands. The Department of Defense Pharmacy and Therapeutics Committee reviews formulary placement annually, and tirzepatide has remained on a higher tier since its FDA approval in May 2022.

How TRICARE Tiers Affect Your Cost

TRICARE uses a three-tier formulary system. Tier 1 includes generics with the lowest copays. Tier 2 holds preferred brand-name drugs. Tier 3 (non-preferred) and specialty tiers carry the highest out-of-pocket costs. Mounjaro falls into this last category.

For TRICARE Prime beneficiaries using a military treatment facility pharmacy, copays can be as low as $0 for formulary drugs. But specialty-tier medications like Mounjaro filled at retail or mail-order pharmacies carry copays ranging from $77 (mail order, 90-day supply) to approximately $334 at a retail network pharmacy for a 30-day fill. These figures shift with annual TRICARE pharmacy updates.

Preferred Alternatives on the TRICARE Formulary

TRICARE's formulary currently lists Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide, the obesity-indication formulation) as covered options with prior authorization for weight management. For type 2 diabetes specifically, older GLP-1 receptor agonists like dulaglutide (Trulicity) and semaglutide (Ozempic) often sit on a preferred tier with lower copays, which is one reason TRICARE may require you try them first.

Prior Authorization Requirements

Every TRICARE prescription for Mounjaro requires prior authorization (PA), regardless of the prescribing indication. Your provider submits clinical documentation to the regional TRICARE contractor, who evaluates whether the request meets coverage criteria.

What the PA Request Must Include

The documentation package typically requires: a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x), a recent HbA1c value (usually above 7.0%), records showing failure or intolerance of metformin, and evidence that at least one other antidiabetic agent was tried. Some regional contractors also ask for body mass index, renal function labs, and a brief treatment rationale from the prescriber.

Timeline and Approval Rates

Standard PA decisions arrive within 5 to 7 business days. Urgent requests, defined as situations where a delay could cause serious harm, are processed within 72 hours. Approval rates for tirzepatide PAs on TRICARE have not been publicly reported, but anecdotal data from military health system pharmacists suggest that requests with complete documentation and clear step therapy history receive approval at rates comparable to other specialty GLP-1 agents.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% compared to 1.86% with semaglutide 1 mg at 40 weeks. This head-to-head superiority data can strengthen a PA submission, especially when prior GLP-1 therapy produced inadequate glycemic control.

Step Therapy: What You Must Try First

TRICARE enforces step therapy for Mounjaro, meaning beneficiaries must demonstrate clinical use of certain lower-cost medications before the plan will authorize tirzepatide.

The Typical Step Therapy Sequence

The standard pathway looks like this:

1. Metformin (first-line therapy per ADA Standards of Care). Most TRICARE contractors require at least 90 days of metformin use or documented intolerance (GI side effects are the most common reason for discontinuation).
2. A second oral agent or GLP-1 RA. Sulfonylureas, SGLT2 inhibitors, or a GLP-1 receptor agonist like dulaglutide or semaglutide. TRICARE often requires at least 90 days on one of these agents.
3. Mounjaro. After documented failure of steps 1 and 2, tirzepatide becomes eligible for PA approval.

Exceptions to Step Therapy

Step therapy can be bypassed in specific clinical scenarios. Documented allergies or contraindications to metformin (such as an eGFR below 30 mL/min/1.73m²), a history of lactic acidosis, or severe adverse reactions to a prior GLP-1 RA may qualify a patient for an exception. Your prescriber must include this documentation in the PA submission.

Coverage for Weight Loss vs. Type 2 Diabetes

This distinction matters. Mounjaro's FDA-approved indication is type 2 diabetes, not obesity or weight management. TRICARE's coverage criteria reflect this.

The Diabetes Pathway

For type 2 diabetes, TRICARE will cover Mounjaro through the PA and step therapy process described above. The clinical bar is clear: confirmed diabetes diagnosis, documented treatment history, and lab values supporting the need for escalation.

The Weight Loss Question

TRICARE does not consistently cover Mounjaro prescribed solely for weight loss. The TRICARE pharmacy benefit excludes most weight-loss medications from standard coverage, though recent policy shifts have added Wegovy and Zepbound with PA for beneficiaries meeting specific obesity-medicine criteria.

If a prescriber writes Mounjaro off-label for obesity (BMI of 30 or greater, or BMI of 27 or greater with a weight-related comorbidity), the claim will likely be denied at the pharmacy level. Some beneficiaries have succeeded on appeal by providing obesity-medicine documentation, including comorbidity records, a structured weight-management plan, and evidence of failed lifestyle intervention. But this path is neither guaranteed nor standardized across TRICARE regions.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% with placebo in adults with obesity. These data underpin Zepbound's FDA approval for chronic weight management, but they do not automatically extend to Mounjaro coverage under TRICARE.

How to Appeal a TRICARE Denial

A denied PA is not the end. TRICARE provides a structured appeal process, and beneficiaries have the right to challenge coverage decisions.

Step-by-Step Appeal Process

First-level appeal. Submit a written appeal to your TRICARE regional contractor within 90 days of the denial. Include the original PA denial letter, updated lab results (especially HbA1c and any metabolic panel changes), a letter of medical necessity from your prescriber, and documentation of prior medication trials with specific dates, doses, and clinical outcomes.

Second-level appeal. If the first appeal is denied, you can escalate to a formal reconsideration. This stage may involve an independent medical review. Providing published clinical evidence (such as the SURPASS trial program data) showing tirzepatide's benefit over agents already tried can support the case.

Third-level review. For TRICARE Prime beneficiaries, a final review can be requested through the Defense Health Agency. This is rare but available for cases with strong clinical justification.

Tips That Improve Appeal Success

Keep records of every medication you have tried, including start dates, end dates, doses, and reasons for discontinuation. A detailed medication history eliminates the most common reason for denial: insufficient documentation of step therapy. Ask your provider to include quantitative data. "HbA1c dropped from 9.2% to 8.4% on semaglutide 1 mg but remains above the 7.0% target" is far more persuasive than "patient needs a stronger medication."

Out-of-Pocket Costs and Savings Options

Without any insurance, Mounjaro's manufacturer list price is $1,023 per month. TRICARE coverage reduces this significantly, but the specialty-tier copay still represents a meaningful expense for some beneficiaries.

TRICARE Cost-Sharing by Plan Type

| Plan | Retail (30-day) | Mail Order (90-day) | |------|-----------------|---------------------| | TRICARE Prime | $77 (non-preferred) | $77 (90-day supply) | | TRICARE Select | $134 to $334 | Lower with Express Scripts home delivery | | TRICARE For Life | Medicare Part D applies first; TRICARE covers remainder | Varies by Part D plan |

These figures are approximate and subject to annual adjustment by the Defense Health Agency.

Manufacturer Savings Card Restrictions

Eli Lilly offers a Mounjaro savings card for commercially insured patients that can reduce copays to as little as $25 per fill. Federal law, however, prohibits the use of manufacturer copay cards with government insurance programs, including TRICARE, Medicare, Medicaid, and VA benefits. This restriction applies even if you fill the prescription at an off-base retail pharmacy.

Alternative Cost-Reduction Strategies

Military treatment facility (MTF) pharmacies dispense formulary medications at $0 copay. If Mounjaro is approved through PA, filling at an MTF pharmacy eliminates cost-sharing entirely. Not all MTF pharmacies stock specialty injectables, so call ahead to confirm availability. The TRICARE Pharmacy Home Delivery program through Express Scripts offers another avenue for lower copays on 90-day fills.

Comparing Mounjaro to Other Covered GLP-1 Options on TRICARE

Beneficiaries weighing their options should understand how tirzepatide compares to the GLP-1 agents TRICARE covers at preferred tiers.

Mounjaro vs. Ozempic

Both target type 2 diabetes. In SURPASS-2, tirzepatide at all three doses (5 mg, 10 mg, 15 mg) produced greater HbA1c reduction than semaglutide 1 mg. Weight loss was also significantly greater with tirzepatide: 7.6 kg to 11.2 kg versus 5.7 kg with semaglutide. Ozempic typically sits on a preferred or lower specialty tier, making it less expensive under TRICARE.

Mounjaro vs. Trulicity

Dulaglutide (Trulicity) is a once-weekly GLP-1 RA that has been on the TRICARE formulary longer and often occupies a preferred tier. In SURPASS-5 (N=475), tirzepatide added to insulin glargine reduced HbA1c by up to 2.59% versus 1.75% with placebo. Direct comparison trials between tirzepatide and dulaglutide are limited, but tirzepatide's dual GIP/GLP-1 mechanism provides additional glucose-dependent insulin secretion that single-incretin agents do not.

When Switching Makes Clinical Sense

If you are stable on Ozempic or Trulicity with an HbA1c at goal, switching to Mounjaro may not be clinically justified, and TRICARE is unlikely to approve the PA. The strongest case for tirzepatide arises when a patient has been on a GLP-1 RA for 90 or more days and has not reached their glycemic target, has experienced intolerable side effects, or requires the additional weight-loss benefit that the dual-agonist mechanism provides.

Special Considerations for Active Duty and Dependents

TRICARE coverage nuances differ based on beneficiary category.

Active Duty Service Members (ADSMs)

ADSMs on TRICARE Prime pay $0 for all formulary prescriptions filled at MTF pharmacies. Non-formulary medications require PA but carry no copay at the MTF. For retail or mail-order fills, ADSMs also pay $0 copay under current policy. This means an approved Mounjaro PA translates to no out-of-pocket drug cost for active duty members.

Dependents and Retirees

Dependents enrolled in TRICARE Prime or TRICARE Select face the tiered copay structure outlined above. Retirees using TRICARE For Life coordinate benefits with Medicare Part D, which adds another layer of formulary review and potential cost-sharing. Retirees should check whether their Part D plan also requires PA for tirzepatide, as both TRICARE and Part D criteria must be satisfied.

According to the Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity, GLP-1 and dual GIP/GLP-1 receptor agonists represent first-line pharmacotherapy for adults with obesity and type 2 diabetes. This guideline can support both PA submissions and appeals for TRICARE beneficiaries who meet the criteria.